Real-world diagnostic performance of blood-based biomarkers for Alzheimer’s disease: robust performance except after stroke and high charlson comorbidity index

Key Points

• To evaluate the diagnostic performance of blood-based biomarkers for Alzheimer's disease in real-world settings.
• Evaluated various blood-based biomarkers for Alzheimer’s disease diagnosis.
• Assessed patient outcomes in relation to stroke and Charlson Comorbidity Index (CCI).
• Analyzed performance metrics of biomarkers across different patient factors.
• Blood-based biomarkers showed overall robust performance for Alzheimer's diagnosis.
• Performance was notably less effective in patients with a history of stroke.
• High Charlson Comorbidity Index (CCI) also indicated a need for caution in diagnosis.